ArticleThe Journal of veterinary medical science2025
Exercise-induced mild rhabdomyolysis associated with oclacitinib in a dog.
Article in The Journal of veterinary medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oclacitinib for Controlling Pruritus and Associated Skin Lesions in 16 Horses With Allergic Dermatitis.Veterinary dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A four-year-old Toy Poodle treated with oclacitinib for one year presented with transient myoglobinuria associated with elevated serum creatine kinase (CK) levels only after exercise. An association between myoglobinuria and oclacitinib was suspected. An exercise stress test with or without oclacitinib was repeated twice on different days. Myoglobinuria and increased serum CK levels occurred only after testing with oclacitinib. The dog was diagnosed with exercise-induced mild rhabdomyolysis, which was presumably provoked by oclacitinib based on the results of the exercise stress tests. Rhabdomyolysis was considered an idiosyncratic adverse event for oclacitinib. This is the first report of exercise-induced mild rhabdomyolysis associated with oclacitinib in a dog.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.